These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 25331784)

  • 1. Proteomic signatures associated with p53 mutational status in lung adenocarcinoma.
    Taguchi A; Delgado O; Celiktaş M; Katayama H; Wang H; Gazdar AF; Hanash SM
    Proteomics; 2014 Dec; 14(23-24):2750-9. PubMed ID: 25331784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LKB1 loss by alteration of the NKX2-1/p53 pathway promotes tumor malignancy and predicts poor survival and relapse in lung adenocarcinomas.
    Tsai LH; Chen PM; Cheng YW; Chen CY; Sheu GT; Wu TC; Lee H
    Oncogene; 2014 Jul; 33(29):3851-60. PubMed ID: 23995788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant large tumor suppressor 2 (LATS2) gene expression correlates with EGFR mutation and survival in lung adenocarcinomas.
    Luo SY; Sit KY; Sihoe AD; Suen WS; Au WK; Tang X; Ma ES; Chan WK; Wistuba II; Minna JD; Tsao GS; Lam DC
    Lung Cancer; 2014 Aug; 85(2):282-92. PubMed ID: 24976335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 gain-of-function mutations increase Cdc7-dependent replication initiation.
    Datta A; Ghatak D; Das S; Banerjee T; Paul A; Butti R; Gorain M; Ghuwalewala S; Roychowdhury A; Alam SK; Das P; Chatterjee R; Dasgupta M; Panda CK; Kundu GC; Roychoudhury S
    EMBO Rep; 2017 Nov; 18(11):2030-2050. PubMed ID: 28887320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PBK/TOPK expression correlates with mutant p53 and affects patients' prognosis and cell proliferation and viability in lung adenocarcinoma.
    Lei B; Qi W; Zhao Y; Li Y; Liu S; Xu X; Zhi C; Wan L; Shen H
    Hum Pathol; 2015 Feb; 46(2):217-24. PubMed ID: 25466965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. microRNA-34a sensitizes lung cancer cell lines to DDP treatment independent of p53 status.
    Wang X; Dong K; Gao P; Long M; Lin F; Weng Y; Ouyang Y; Ren J; Zhang H
    Cancer Biother Radiopharm; 2013 Feb; 28(1):45-50. PubMed ID: 23036084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1α/Nrf2 pathway, leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents.
    Do MT; Kim HG; Choi JH; Jeong HG
    Free Radic Biol Med; 2014 Sep; 74():21-34. PubMed ID: 24970682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lung tumors with distinct p53 mutations respond similarly to p53 targeted therapy but exhibit genotype-specific statin sensitivity.
    Turrell FK; Kerr EM; Gao M; Thorpe H; Doherty GJ; Cridge J; Shorthouse D; Speed A; Samarajiwa S; Hall BA; Griffiths M; Martins CP
    Genes Dev; 2017 Jul; 31(13):1339-1353. PubMed ID: 28790158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NKX2-1-mediated p53 expression modulates lung adenocarcinoma progression via modulating IKKβ/NF-κB activation.
    Chen PM; Wu TC; Cheng YW; Chen CY; Lee H
    Oncotarget; 2015 Jun; 6(16):14274-89. PubMed ID: 25881545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RUNX3 downregulation in human lung adenocarcinoma is independent of p53, EGFR or KRAS status.
    Omar MF; Ito K; Nga ME; Soo R; Peh BK; Ismail TM; Thakkar B; Soong R; Ito Y; Salto-Tellez M
    Pathol Oncol Res; 2012 Oct; 18(4):783-92. PubMed ID: 22729835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
    Sun H; Liu SY; Zhou JY; Xu JT; Zhang HK; Yan HH; Huan JJ; Dai PP; Xu CR; Su J; Guan YF; Yi X; Yu RS; Zhong WZ; Wu YL
    EBioMedicine; 2020 Oct; 60():102990. PubMed ID: 32927274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant p53
    Hernández-Reséndiz I; Gallardo-Pérez JC; López-Macay A; Robledo-Cadena DX; García-Villa E; Gariglio P; Saavedra E; Moreno-Sánchez R; Rodríguez-Enríquez S
    J Cell Physiol; 2019 May; 234(5):5524-5536. PubMed ID: 30272821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LKB1 Loss induces characteristic patterns of gene expression in human tumors associated with NRF2 activation and attenuation of PI3K-AKT.
    Kaufman JM; Amann JM; Park K; Arasada RR; Li H; Shyr Y; Carbone DP
    J Thorac Oncol; 2014 Jun; 9(6):794-804. PubMed ID: 24828662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Id2 gene is a transcriptional target of the protein complex mutant p53/E2F1.
    Fontemaggi G; Dell'Orso S; Muti P; Blandino G; Strano S
    Cell Cycle; 2010 Jun; 9(12):2464-6. PubMed ID: 20519942
    [No Abstract]   [Full Text] [Related]  

  • 15. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
    Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
    Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of MAGEA2 has a prognostic significance and is a potential therapeutic target for patients with lung cancer.
    Ujiie H; Kato T; Lee D; Hu HP; Fujino K; Kaji M; Kaga K; Matsui Y; Yasufuku K
    Int J Oncol; 2017 Jun; 50(6):2154-2170. PubMed ID: 28498455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential Predictive Value of
    Dong ZY; Zhong WZ; Zhang XC; Su J; Xie Z; Liu SY; Tu HY; Chen HJ; Sun YL; Zhou Q; Yang JJ; Yang XN; Lin JX; Yan HH; Zhai HR; Yan LX; Liao RQ; Wu SP; Wu YL
    Clin Cancer Res; 2017 Jun; 23(12):3012-3024. PubMed ID: 28039262
    [No Abstract]   [Full Text] [Related]  

  • 18. Fas-mediated apoptosis is dependent on wild-type p53 status in human cancer cells expressing a temperature-sensitive p53 mutant alanine-143.
    Li Y; Raffo AJ; Drew L; Mao Y; Tran A; Petrylak DP; Fine RL
    Cancer Res; 2003 Apr; 63(7):1527-33. PubMed ID: 12670900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 suppression is essential for oncogenic SPAG5 upregulation in lung adenocarcinoma.
    Wang T; Li K; Song H; Xu D; Liao Y; Jing B; Guo W; Hu M; Kuang Y; Sun B; Ling J; Zhang T; Xu J; Yao F; Deng J
    Biochem Biophys Res Commun; 2019 May; 513(2):319-325. PubMed ID: 30955859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical significance of mutant p53 protein expression in lung adenocarcinoma].
    Bian C; Li Z; Xu Y; Wang J; Xu L; Shen H
    Zhongguo Fei Ai Za Zhi; 2015 Jan; 18(1):23-8. PubMed ID: 25603869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.